



NDA 021446/S-026  
NDA 022488/S-005

## SUPPLEMENT APPROVAL

C.P. Pharmaceuticals International C.V.  
c/o Pfizer, Inc.  
455 Eastern Point Road  
Groton, CT 06340

Attention: Imran Shah  
Associate Director  
Worldwide Regulatory Strategy

Dear Mr. Shah:

Please refer to your Supplemental New Drug Application (sNDA) dated and received June 2, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for LYRICA<sup>®</sup> (pregabalin) Capsules and Oral Solution.

This Prior Approval supplemental application proposes changes to the “**What is the most important information I should know about LYRICA?**” section of the Medication Guide so as to furnish adequate information for the safe and effective use of the drug, as requested in the FDA Prior Approval Supplement Request letter dated May 5, 2011.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement numbers and annual report dates.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Diana L. Walker, PhD, Regulatory Health Project Manager, at (301) 796-4029.

Sincerely,

*{See appended electronic signature page}*

Sharon Hertz, M.D.  
Deputy Director  
Division of Anesthesia, Analgesia and  
Addiction Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

ENCLOSURE(S):

Package Insert

Medication Guide

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

SHARON H HERTZ  
06/20/2011